This HTML5 document contains 116 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
n12http://dx.doi.org/10.1007/
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
n9https://scigraph.springernature.com/pub.10.1007/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q64231015
rdf:type
wikibase:Item
schema:description
article scientifique publié en 2019 artículu científicu espublizáu en xineru de 2019 scientific article published on 10 January 2019 im Januar 2019 veröffentlichter wissenschaftlicher Artikel 2019 թվականի հունվարի 10-ին հրատարակված գիտական հոդված wetenschappelijk artikel наукова стаття, опублікована в березні 2019
p:P577
wds:Q64231015-77ECAA70-427A-4CF7-9627-BD37BDB57EB6
wdt:P577
2019-01-10T00:00:00Z
p:P407
wds:Q64231015-A21BBD09-51DA-4EEC-A13C-62C9A74C8838
wdt:P407
wd:Q1860
p:P2888
wds:Q64231015-A75EE85E-B8E4-483A-B681-58D3B376BD53
wdt:P2888
n9:s40744-018-0138-y
p:P2860
wds:Q64231015-03003B96-E063-42D9-9DE2-42D09E0B0F12 wds:Q64231015-196D153D-3455-4C5D-819B-CDBFE0AEB2CE wds:Q64231015-59E31927-1463-404C-80C0-E2BCDAB395E1 wds:Q64231015-670BC3E6-65D1-4C76-B5EE-678511EEE7EA wds:Q64231015-6F3FD34C-E9FD-48D9-A412-23478C52A2B0 wds:Q64231015-268EAEA1-5FAF-4412-BA95-E583045763EC wds:Q64231015-36046C94-1795-44C1-AEDB-6B7472D0910F wds:Q64231015-3BF61BC8-304E-49A3-8162-97B9976F3223 wds:Q64231015-90577F9F-4E16-4B59-8F7F-6ADCF5EBF6DD wds:Q64231015-92971F45-D9E4-4A4A-9125-7AE860E0BE18 wds:Q64231015-94FBD16D-1372-4627-A68D-0D32B92C5080 wds:Q64231015-98F84819-4E71-4AE7-9C23-6A6E8197B60A wds:Q64231015-A8230B29-5E4E-450B-9208-2F74B975766F wds:Q64231015-7C373B6F-4DD4-4282-9B78-DCFE732AFA52 wds:Q64231015-84283F83-A83F-424C-A8C1-0BF075285B8C wds:Q64231015-89F09C74-F0C1-434F-961F-12E01077855E wds:Q64231015-B3C29392-D50D-41CF-AB98-FDF523A61024 wds:Q64231015-BCCD57F0-A19E-40AF-8931-59FD632ED6C7 wds:Q64231015-D6070C93-7FDF-4C2E-AC7A-514293FF5386 wds:Q64231015-D699AD69-97CB-40EE-8D04-ED09632CB2AA
wdt:P2860
wd:Q47292924 wd:Q35554799 wd:Q36059484 wd:Q34477442 wd:Q37320282 wd:Q78794833 wd:Q37465508 wd:Q41685017 wd:Q95367811 wd:Q55049410 wd:Q47970691 wd:Q84916829 wd:Q35827701 wd:Q43957207 wd:Q40167433 wd:Q24630541 wd:Q28295371 wd:Q34770459 wd:Q34795777 wd:Q42090806
p:P2093
wds:Q64231015-F53D3F44-4ACA-42AA-B478-C6D91E80D215 wds:Q64231015-DFC9F736-6F51-4189-A2BA-F9BB6FD1348C wds:Q64231015-DA0DA164-91B6-427C-B48C-8EF59D06BB25 wds:Q64231015-DC37C2B0-AFB7-4101-AAC7-EE03AF6FB65A wds:Q64231015-CB0A65D7-638F-4F57-9BB5-BDAA806AB123 wds:Q64231015-989FE0A3-0BD4-4C2C-9B17-55EA2362E813 wds:Q64231015-884EC4A7-97DD-4E19-BFAF-B4A15411753D wds:Q64231015-6596D0B6-5F04-408D-B399-C202320DADC4 wds:Q64231015-60854120-7890-4AFD-AB66-3BA0154F687E wds:Q64231015-3D34D0EA-33C5-499A-8D2D-462828CFCA40 wds:Q64231015-4FA12C34-3024-4AC5-A1C7-103A8E080B3B wds:Q64231015-3971F94F-183F-4E46-9B06-53BDBEE45921 wds:Q64231015-2E149BBC-29F5-415E-B7B9-F2DF2CEB11A0 wds:Q64231015-06707AF3-5814-4EAE-9CF1-90994F12402A
wdt:P2093
René-Marc Flipo Guy Baudens Samuel Gally Xavier Deprez Jean Darloy Marie-Hélène Guyot Isabelle Idier David Pau Jean-Paul Eschard Nicolas Segaud Nicolas Lecuyer Laurent Marguerie Jean-Hugues Salmon Eric Houvenagel
rdfs:label
Tocilizumab Effectiveness After Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis: The RoSwitch Study Tocilizumab Effectiveness After Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis: The RoSwitch Study
skos:prefLabel
Tocilizumab Effectiveness After Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis: The RoSwitch Study Tocilizumab Effectiveness After Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis: The RoSwitch Study
schema:name
Tocilizumab Effectiveness After Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis: The RoSwitch Study Tocilizumab Effectiveness After Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis: The RoSwitch Study
p:P50
wds:Q64231015-80738BEB-2F83-46FF-A32F-79C7EEBC5151
wdt:P50
wd:Q56419836
p:P1476
wds:Q64231015-A8E08E30-17E5-4A34-BE1E-5F99723A8374
wdt:P1476
Tocilizumab Effectiveness After Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis: The RoSwitch Study
p:P304
wds:Q64231015-55DD6745-AEC4-4557-98F7-F35AE78D199A
wdt:P304
61-75
p:P31
wds:Q64231015-E4AED2F1-1F92-43C3-9E47-BB8175EE35F2
wdt:P31
wd:Q13442814
p:P921
wds:Q64231015-F8A87129-D416-481A-8F1F-AB22F48A8DF7 wds:Q64231015-7DE2D38D-A93A-4514-86C5-AAEF9D76780E
wdt:P921
wd:Q187255 wd:Q425154
p:P698
wds:Q64231015-1C1F285C-E1A7-47D9-AD04-594C6CCEDFF5
wdtn:P698
n5:30632015
wdt:P698
30632015
p:P1433
wds:Q64231015-B9B52606-A27D-4152-A94F-00B25BFEB18D
wdt:P1433
wd:Q27727370
p:P433
wds:Q64231015-775F148C-AE06-4E2B-9186-120844BD4787
p:P478
wds:Q64231015-E0111F25-8FA9-4D49-82EC-4AA3005285CD
wdt:P433
1
wdt:P478
6
p:P356
wds:Q64231015-8A780781-2C9E-4F7F-837F-24DD8C56436B
wdtn:P356
n12:S40744-018-0138-Y
wdt:P356
10.1007/S40744-018-0138-Y
p:P6179
wds:Q64231015-5C95C7FF-B4A0-426D-8C30-D33D2075C77B
wdt:P6179
1111318265
p:P932
wds:Q64231015-B9670AEB-855D-43AC-9099-EFA9FE803351
wdt:P932
6393270